CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that its Chairman and Director, Mr. Choo Chee Kong, entered into a binding private share purchase agreement on May 13, 2026 to acquire 112,000 ordinary shares of the company from an independent arm's-length shareholder for cash consideration.

The transaction was a privately negotiated deal between Mr. Choo and the shareholder. The company was not a party to the transaction and did not receive any proceeds. Mr. Choo intends to negotiate privately with additional independent arm's-length shareholders to further increase his shareholding.

Insights

Corporate governance analyst

Chairman increases personal stake via private share purchase.

The filing describes a binding private agreement under which Chairman Choo Chee Kong acquires 112,000 ordinary shares from an independent shareholder for cash. The company itself is not involved and does not receive proceeds, so there is no direct balance-sheet impact.

Because this is a secondary transaction between existing holders, it does not change the total shares outstanding but does concentrate ownership further with the chair. The filing also notes his intention to seek more privately negotiated purchases, so future reports may show additional shifts in the ownership structure.

Key Figures

Shares acquired: 112,000 ordinary shares Filing type: Form 6-K Date of agreement: May 13, 2026 +1 more

4 metrics

Shares acquired 112,000 ordinary shares Binding private share purchase agreement on May 13, 2026

Filing type Form 6-K Report of foreign private issuer for May 2026

Date of agreement May 13, 2026 Date Chairman entered private share purchase agreement

Signature date May 15, 2026 Date the report was signed by the Chairman and Director

Key Terms

binding private share purchase agreement, privately negotiated transaction, independent arm-length shareholder, foreign private issuer

4 terms

binding private share purchase agreement financial

"entered into a binding private share purchase agreement with an independent arm-length shareholder"

privately negotiated transaction financial

"for cash consideration pursuant to a privately negotiated transaction"

A privately negotiated transaction is a deal whose terms are worked out directly between a buyer and a seller rather than through a public market or open auction. Think of it like selling a car to a neighbor instead of putting it on eBay: the price, timing and conditions are agreed one-on-one, so investors may see less public information, different pricing compared with market trades, and potential impacts on liquidity and valuation.

independent arm-length shareholder financial

"with an independent arm-length shareholder to acquire 112,000 ordinary shares"

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On May 13, 2026, Mr. Choo Chee Kong, Chairman and Director of the Company, entered into a binding private share purchase agreement with an independent arm-length shareholder   to acquire 112,000 ordinary shares of the Company for cash consideration pursuant to a privately negotiated transaction. The Company was not a party to the transaction and did not receive any proceeds therefrom. Mr Choo intends to negotiate privately with more independent arm-length shareholders to increase his shareholding in the Company.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: May 15, 2026	Title:	Director and Chairman

FAQ

What transaction did CytoMed Therapeutics (GDTC) disclose in this 6-K?

CytoMed disclosed that Chairman Choo Chee Kong entered a binding private share purchase agreement to acquire 112,000 ordinary shares for cash from an independent arm’s-length shareholder. The deal is a secondary transaction between existing holders, not a new share issuance by the company.

How many CytoMed Therapeutics (GDTC) shares did the chairman agree to buy?

Chairman Choo Chee Kong agreed to buy 112,000 ordinary shares of CytoMed Therapeutics. These shares are being purchased from an independent arm’s-length shareholder through a privately negotiated transaction, according to the company’s May 2026 report as a foreign private issuer.

Did CytoMed Therapeutics (GDTC) receive any proceeds from the chairman’s share purchase?

CytoMed did not receive any proceeds from this transaction. The 6-K states the company was not a party to the privately negotiated deal, which occurred directly between Chairman Choo Chee Kong and an independent arm’s-length shareholder for cash consideration.

What are Chairman Choo Chee Kong’s future intentions regarding CytoMed (GDTC) shares?

The filing states that Mr. Choo intends to negotiate privately with more independent arm’s-length shareholders to increase his shareholding. This suggests he may pursue additional secondary purchases, which could further concentrate ownership without changing total shares outstanding.

When was the CytoMed Therapeutics (GDTC) private share purchase agreement entered into?

The agreement was entered into on May 13, 2026. On that date, Chairman Choo Chee Kong and an independent arm’s-length shareholder agreed on a binding private share purchase for 112,000 ordinary shares, as disclosed in CytoMed’s May 2026 Form 6-K filing.